SEP 4, 2026 · JOURNAL ARTICLE
Generation and characterization of a CEACAM5 x CDH17 x CD3 tri-specific T-Cell engager for colorectal cancer therapy
Antibody Therapeutics
First-in-class tri-specific T-cell engager showing promising preclinical efficacy in xenograft models, but lacks human clinical data and relies on surrogate endpoints and animal studies.
Reported
CEACAM5 binding affinity (human)51.0 nM
CEACAM5 binding affinity (cynomol…109 nM
CDH17 binding affinity (human)42.8 nM